KEGG   NETWORK: N00247Help
Entry
N00247                      Network                                

Name
HGF-overexpression to PI3K signaling pathway
Definition
HGF* -> MET -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD
  Expanded
3082v1 -> 4233 -> 2549 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -| 572
Class
nt06214 PI3K signaling
nt06263 Hepatocellular carcinoma
Type
Variant
Pathway
hsa05225  Hepatocellular carcinoma
Disease
H00048  Hepatocellular carcinoma
Gene
3082  HGF; hepatocyte growth factor
4233  MET; MET proto-oncogene, receptor tyrosine kinase
2549  GAB1; GRB2 associated binding protein 1
5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
207  AKT1; AKT serine/threonine kinase 1
208  AKT2; AKT serine/threonine kinase 2
10000  AKT3; AKT serine/threonine kinase 3
572  BAD; BCL2 associated agonist of cell death
Variant
3082v1  HGF overexpression
Metabolite
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Breuhahn K, Longerich T, Schirmacher P
  Title
Dysregulation of growth factor signaling in human hepatocellular carcinoma.
  Journal
Oncogene 25:3787-800 (2006)
DOI:10.1038/sj.onc.1209556
Reference
  Authors
Harding JJ, Abou-Alfa GK
  Title
Systemic therapy for hepatocellular carcinoma.
  Journal
Chin Clin Oncol 2:37 (2013)
DOI:10.3978/j.issn.2304-3865.2013.07.06
Reference
  Authors
Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ
  Title
The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.
  Journal
Onco Targets Ther 7:969-83 (2014)
DOI:10.2147/OTT.S40241
Reference
  Authors
Lee D, Sung ES, Ahn JH, An S, Huh J, You WK
  Title
Development of antibody-based c-Met inhibitors for targeted cancer therapy.
  Journal
Immunotargets Ther 4:35-44 (2015)
DOI:10.2147/ITT.S37409

DBGET integrated database retrieval system